403 TGW participated; 52.1% were aged 18–33 years; mean 34.4 (SD ± 9.6); 57.6% had ≥ 12 years of formal education; 70% identified as black/mixed race; 25.8% declared sex work as main source of income and 48.1% that their monthly income was below or equal to the Brazilian minimum wage. Prevalence of chlamydia and gonorrhea was, respectively, 10.2% (41/403) and 8.2% (33/403); coinfection was 2.4% (10/403). Most TGW testing positive had anal infections: 90.2% for chlamydia and 66.7%, gonorrhea. Prevalence of chlamydia or gonorrhea was slightly higher among individuals living with HIV (18% vs 15% among HIV-negative individuals, OR 1.21; 95% CI 0.67 – 2.19). After adjusting for schooling, sex work as main source of income, and monthly income, young age remained a risk factor for a chlamydia (aOR 2.78; 95% CI 1.34 – 5.74) and gonorrhea (aOR 2.21; 95% CI 1.02 – 4.79) diagnosis.

Chlamydia and gonorrhoea prevalence is high among Brazilian TGW, especially amongst the young. Comprehensive care and prevention programs, including sexual education and screening policies directed at TGW are urgently needed to reduce STI burden and to interrupt STI/HIV transmission.

015.6 'IF THEY ASK, I WILL TELL THEM': ATTITUDES TOWARDS ACCESSING SEXUAL HEALTHCARE AMONG HETEROSEXUAL-IDENTIFYING MSM IN ENGLAND

¹T Curtis*, ¹C Mercer, ¹N Field, ²L McDonagh. ¹University College London, Institute for Global Health, London, UK; ²University College London, NIHR Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, London, UK

10.1136/sextrans-2021-sti.139

Background STI/HIV testing is lower among heterosexual-identifying men who have sex with men (heterosexual-MSM) than bisexual or gay men. We aimed to understand attitudes towards sexual healthcare among heterosexual-MSM in England, to improve service design and uptake among this overlooked population.

Methods Semi-structured individual interviews were conducted with 15 heterosexual-MSM in England in January–March 2020. Participants ranged in age from 22–69 years. All but one reported current or previous relationships with women. Data were analysed using an inductive thematic analysis.

Results Frequency of STI/HIV testing varied widely between participants, reflecting how some men felt they lacked sufficient or accurate information about testing guidelines and options, including the possibility of home-sampling/testing. Among men with female partners, concern for the health and wellbeing of these partners was a motivator for testing. However, privacy and discretion were important factors in the use of home-sampling/testing kits for men living with female partners or family; their ability to use these services was limited when their privacy needs were not accommodated. Their heterosexual identity meant some felt services intended for gay and bisexual men were not appropriate for them. If asked by sexual health clinicians, most heterosexual-MSM interviewed reported feeling comfortable disclosing the sex they have with men, describing the impersonal nature of consultations and perceptions of non-judgement and discretion as facilitators for disclosure. However, this comfort with disclosure did not

always extend to GPs, due to fears their behaviour would be exposed to others.

Conclusion For the heterosexual-MSM in this study, privacy and discretion were of utmost importance. These must be guaranteed by sexual healthcare services, whether in-clinic or home-sampling/testing, to appeal to MSM regardless of their personal circumstances. Trust in clinician confidentiality and non-judgement facilitate disclosure. Further work is needed to identify ways for sexual health services to appeal to, and reach, this population.

Female reproductive health for STIs and HIV

016.1 HIGH BURDEN OF REPRODUCTIVE TRACT INFECTIONS AND POOR SEXUAL AND REPRODUCTIVE HEALTH IN PREGNANCY AND POSTPARTUM IN PAPUA NEW GUINEA

^{1,2}M Scoullar*, ¹P Boeuf, ¹E Peach, ¹E Kearney, ¹R Fidelis, ¹K Tokmun, ¹P Melepie, ^{2,3,4}C Bradshaw, ⁵A Elijah, ³G Fehler, ⁶P Siba, ⁷S Erskine, ⁷E Mokany, ¹E Kennedy, ¹A Umbers, ^{1,8,9}S Luchters, ^{1,2,4,6}L Robinson, ⁴N Wong, ^{6,10}A Valley, ¹⁰S Badman, ^{10,11}L Valley, ^{1,2,4}F Fowkes, ¹C Morgan, ⁶W Pomat, ^{1,2,4}B Crabb, ^{1,2,4}J Beeson, H Study Team. ¹Burnet Institute, Australia; ²University of Melbourne, Melbourne, Australia; ³Melbourne Sexual Health Centre, Alfred Hospital, Australia; ⁴Monash University, Melbourne, Australia; ⁵School of Medicine and Health Sciences, University of Papua New Guinea, Papua New Guinea; ⁶Papua New Guinea Institute of Medical Research, Papua New Guinea; ⁷SpeedX Pty Ltd, Australia; ⁸Department of Population Health, Aga Khan University, Nairobi, Kenya; ⁹International Centre for Reproductive Health, Department of Public Health and Primary Care, Ghent University, Belgium; ¹⁰The Kirby Institute, University of New South Wales, Australia; ¹¹Australian Institute of Tropical Health and Medicine, James Cook University, Townsville

10.1136/sextrans-2021-sti.140

There is a pressing need for detailed knowledge of the range of pathogens, extent of co-infection and clinical impact of reproductive tract infections (RTIs) among pregnant women. We present prevalence and correlates of RTIs (*Mycoplasma genitalium*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Trichomonas vaginalis*, *Treponema pallidum* subspecies *pallidum*, bacterial vaginosis and vulvovaginal candidiasis) in a longitudinal study of women in pregnancy and postpartum in Papua New Guinea (PNG).

699 pregnant women were recruited at their first antenatal clinic visit and followed up at childbirth, one, six and twelve months postpartum. Self-collected vaginal swabs were tested for *M. genitalium* using real-time PlexPCR® (SpeedX) which provides results for five point mutations associated with macrolide resistance. Urine samples or vaginal swabs were tested for *C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis* using GeneXpert. A vaginal smear was examined for BV and VVC. Routine antenatal services tested for syphilis using Alere Determine™ Syphilis.

Most pregnant women (74.1%) had at least one RTI, with a curable current sexually-transmitted infection (STI) detected in 37.7%. We found *M. genitalium*, an emerging pathogen in PNG, in 12.5% of pregnant women, decreasing to 6.1% at six months postpartum, with no evidence of macrolide resistance. Prevalence of other curable STIs (*C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis*) were all high in pregnancy

(19.1%, 5.5% and 20.1% respectively), with prevalence decreasing immediately postpartum but rising again by 12 months postpartum. Clinical symptoms missed at least 75% of infections and there was little use of contraception; 98.4% report never having used barrier contraception.

This study highlights a high prevalence of a RTIs in pregnancy and postpartum. Most of these infections are curable when diagnosis is made available and syndromic management alone is insufficient. This high prevalence of disease negatively affects sexual and reproductive health and these findings have important public health implications in PNG and the region.

O16.2 EPISODIC PREP USE AMONG YOUNG WOMEN IN SIAYA COUNTY, KENYA

A Corneli*, B Perry, D Ochieng Ngoje, N Molokwu, K Agot. *Duke University, Durham, USA*

10.1136/sextrans-2021-sti.141

Introduction The DREAMS Initiative provides PrEP to young women (YW) in Siaya County, Kenya, to combat the region's high HIV incidence. Women must take PrEP consistently for three weeks for full protection; episodic use may diminish PrEP's effectiveness. We describe findings on episodic PrEP use from participatory-based research to identify multi-level factors influencing YW's PrEP use.

Methods Using photovoice, YW and four groups in their social ecology—female peers, male peers/partners, family, and community members, including healthcare providers—participated in four iterative activities. First, participants photographed factors influencing YW's PrEP persistence. Second, participants discussed photographs with their own group (e.g., YW discussed with other YW). Third, YW and members in other groups (e.g., female peers) discussed each other's photographs and answered questions on themes from previous discussions. Fourth, YW shared individual experiences on themes during in-depth interviews. All discussions/interviews were audio-recorded, simultaneously translated/transcribed, and analyzed using applied thematic analysis. We focus on data from YW and female peers.

Results During group discussions, YW and female peers (n=27) explained that YW perceive male partners as the primary source of HIV risk. As a result, YW commonly stop taking PrEP when partners are away for a few days to several weeks; they start taking PrEP again the day their partners return. Participants stressed that taking PrEP consistently for three weeks may be difficult for some because YW are unaware of their partners' return date and husbands' unwillingness to delay sex. Among YW interviewed (n=18), nearly all their partners traveled, and about one-third reported stopping PrEP during their partners' absences. Reasons two-thirds continue include not knowing partners' sexual behaviors when traveling, and because PrEP provides HIV protection in case of accidents or rape.

Conclusion Counseling on PrEP persistence during partners' short absences is essential for PrEP to be most effective among YW in Kenya.

O16.3 HIGH PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS AMONG YOUNG AFRICAN WOMEN IN REACH STUDY OF ORAL EMTRICITABINE-TENOFOVIR AND DAPIVRINE VAGINAL RING

¹C Akello*, ²D Szydlo, ³P Macdonald, ⁴B Siziba, ⁵T Palanee-Phillips, ⁶M Garcia, ⁶T McClure, ⁷S Johnson, ⁷L Levy, ⁸K Nguire, ³G Nair, ⁹EL Soto-Torres, ²RE Brown, ^{10,11}C Celum, ^{3,11,12}EJ Balkus. ¹Makerere University Johns Hopkins Research Collaboration, Kampala, Uganda; ²Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, USA; ³Desmond Tutu HIV Centre, University of Cape Town, Emavundleni Research Centre, CapeTown, South Africa; ⁴University of Zimbabwe-Clinical Trials Research Centre, Harare, Zimbabwe; ⁵Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ⁶Family Health International 360 (FHI360), Durham, USA; ⁷Family Health International 360 (FHI360), Washington DC, USA; ⁸Jomo Kenyatta University of Agriculture and Technology, College of Health Sciences, Nairobi, Kenya; ⁹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA; ¹⁰Department of Medicine, University of Washington, Seattle, USA; ¹¹Department of Global Health, University of Washington, Seattle, USA; ¹²Department of Epidemiology, University of Washington, Seattle, USA

10.1136/sextrans-2021-sti.142

Background With antiretroviral (ARV)-based HIV prevention, the hidden epidemic of sexually transmitted infections (STIs) is being uncovered. Most STIs are asymptomatic and not treated by syndromic case management, the standard of care in Africa. There are limited data on STI prevalence among African adolescent girls and young women (AGYW) who are at risk for sequelae from untreated STIs.

Methods MTN-034/REACH is a randomized, open label, crossover study assessing the safety of and adherence to the dapivirine vaginal ring and oral emtricitabine-tenofovir in Cape Town and Johannesburg, South Africa, Kampala, Uganda and Harare, Zimbabwe. Sexually active HIV-negative AGYW ages 16–21 years were enrolled and tested for Chlamydia trachomatis/Neisseria gonorrhoeae (CT/GC) by nucleic acid amplification, Trichomonas vaginalis (TV) by rapid test, and syphilis by serology. AGYW with positive test results received treatment. Descriptive statistics were used to summarize STI prevalence at baseline and selected characteristics by STI status.

Results Among 247 AGYW enrolled in REACH, 34% were 16–17 years old, 87% single, and the median number of sexual partners in the prior 3 months was 1 (IQR 1–2). At enrollment, 87 (35%) tested positive for any STI with 17 (7%) with >1 STI: 71 (29%) for CT, 21 (8.5%) for GC, 12 (4.9%) for TV and 6 (2.4%) for syphilis. Of AGYW diagnosed with an STI, 90% were asymptomatic. The prevalence of any STI varied by site: 47% in Cape Town, 37% in Johannesburg, 32% in Kampala, and 25% in Harare. STI prevalence was higher among 18–21 year olds versus 16–17 year olds (37% vs 32%).

Conclusion STI prevalence among AGYW initiating oral or topical PrEP was alarmingly high and most were asymptomatic, highlighting the limitations of syndromic STI management. There is an urgent need and imperative to provide diagnostic STI testing to AGYW with the delivery of HIV prevention methods.